Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Alpha-1 Antitrypsin Deficiency
Emphysema

Interventions: Drug: Aspirin
Drug: Placebo
Other: Withdrawal from alpha1 antitrypsin replacement therapy

Registration Number: NCT03008915

Lead Sponsor: Columbia University

Brief Summary: The aim of this study is to test whether aspirin improves endothelial function in alpha-1 antitrypsin deficiency-associated lung disease, measured by pulmonary microvascular blood flow on magnetic resonance imaging (MRI) and with apoptotic endothelial microparticles.

Detailed Description: Emphysema is a common type of lung disease in patients with alpha-1 antitrypsin deficiency (AATD). Emphysema refers to destruction of the fine network of air spaces and blood vessels in the lung, and results in what looks like "holes" in the lung. Emphysema is associated with an increased risk of death but currently no medications, except for replacement of alpha-1 antitrypsin (AAT), have been shown to treat emphysema.

The study plans to enroll subjects with alpha-1 antitrypsin deficiency-associated lung disease (PiZZ phenotype) to perform a cross-over randomized controlled trial (RCT) of aspirin compared to placebo to test the hypotheses that aspirin is effective in improving blood flow in the lungs and reducing damage to the endothelial cells. Subjects will be randomized to receive aspirin or placebo for 2 weeks. There will be a 2-week washout period, then the participant will be crossed over to receive the other treatment (those who received aspirin first will receive the placebo and those who received the placebo first will receive aspirin).

Participants who are on alpha-1 replacement therapy who have had fewer than 2 exacerbations in the last year will be asked whether they are interested in a withdrawal study. For this second part of the study, eligible and willing participants will be asked to stop their alpha-1 replacement therapy for 5 weeks and come in for a 4th study visit. This will allow AAT levels to drop briefly to those seen in the absence of AAT augmentation.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 15

Inclusion Criteria

Alpha-1 antitrypsin deficiency (PiZZ genotype)
40 years of age or older
Evidence of emphysema on CT scan as read by a Radiologist

Exclusion Criteria

Platelet count < 150,000/dL, history of intracranial hemorrhage or severe GI bleed, use of systemic anticoagulant, physician prescribed use of antiplatelet drug (including aspirin and P2Y12 receptor inhibitors), or known severe liver disease
Immunosuppression by use of medications (including oral prednisone), or those with immunomodulatory disease (organ transplantation, autoimmune conditions or actively-treated malignancy)
Known atrial fibrillation or left ventricular (LV) systolic heart failure
Contraindication to MRI, including pregnancy, weight > 300 lbs (due to weight limits of the machine), those with pacemakers, aneurysm clips, cochlear implants or other implanted electronic devices, or severe claustrophobia;
Chronic renal insufficiency (estimated GFR < 45 L/min/1.73 m2 or self report) due to slightly increased risk of nephrogenic systemic fibrosis from gadolinium administration and aspirin-related renal insufficiency
Exacerbation of respiratory symptoms within the previous 6 weeks, such as that requiring hospitalization, oral prednisone or antibiotics to control symptoms.

Study & Design

Study Type: INTERVENTIONAL

Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo first then aspirin	Placebo	Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
Aspirin first then placebo	Placebo	Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
Aspirin first then placebo	Withdrawal from alpha1 antitrypsin replacement therapy	Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
Placebo first then aspirin	Withdrawal from alpha1 antitrypsin replacement therapy	Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
Aspirin first then placebo	Aspirin	Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
Placebo first then aspirin	Aspirin	Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks

Primary Outcome Measures

Name	Time	Method
Pulmonary Microvascular Blood Flow, Mean	2 weeks	Pulmonary microvascular blood flow is measured on contrast-enhanced MRI, limited to blood flow in the 2cm periphery of the lung

Secondary Outcome Measures

Name	Time	Method
Endothelial Microparticles	5 weeks	Endothelial microparticles (EMPs) are vesicles shed from endothelial plasma membranes into the circulation in response to endothelial cell perturbation. CD31+ is a measure of apoptotic endothelial microparticles, CD62+ (P-selectin) is a measure of endothelial activation, and Annexin V/CD31+ is a more specific marker of endothelial cell apoptosis.
Pulmonary Microvascular Blood Flow, Mean	5 weeks	Pulmonary microvascular blood flow is measured on contrast-enhanced MRI in the peripheral 2cm of the lung.